华氏巨球蛋白血症治疗的新进展
New developments in the management of Waldenström macroglobulinemia.
作者信息
Abeykoon Jithma P, Yanamandra Uday, Kapoor Prashant
机构信息
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Hematology and Stem Cell Transplant, Army Hospital (Research & Referral), Delhi, India.
出版信息
Cancer Manag Res. 2017 Mar 10;9:73-83. doi: 10.2147/CMAR.S94059. eCollection 2017.
Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton's tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.
华氏巨球蛋白血症（WM）是一种罕见的、与免疫球蛋白M相关的淋巴浆细胞性淋巴瘤。随着近期疣、低丙种球蛋白血症、感染和白细胞噬菌作用（WHIM）及相关突变的发现，我们对WM生物学特性的认识有了显著扩展。虽然WM仍然无法治愈，但该领域正在迅速发展，目前正在评估一些对这种恶性肿瘤具有显著活性的有前景的药物。在这篇综述中，我们讨论过去15年中WM出现的新进展，重点关注伊布替尼的作用，伊布替尼是一种口服布鲁顿酪氨酸激酶抑制剂，最近已在美国、欧洲和加拿大被批准用于WM的治疗。
Zotero 插件